Correspondence 0001104659-24-072518 from ALUMIS INC. (ALMS)
ALUMIS INC.
Date: June 18, 2024 · CIK: 0001847367 · Accession: 0001104659-24-072518
AI Filing Summary & Sentiment
Referenced dates: June 17, 2024
Show Raw Text
CORRESP
1
filename1.htm
David Peinsipp
T: (415) 693 2177
dpeinsipp@cooley.com
June 18, 2024
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Jessica Dickerson
Franklin Wyman
Kevin Vaughn
Tim Buchmiller
Re: Alumis Inc.
Registration Statement on
Form S-1
Filed on June 7, 2024
CIK No. 0001847367
Ladies and Gentlemen:
On behalf of Alumis Inc. (the “Company”),
the following information is submitted in response to the comments received from the staff (the “Staff”) of
the U.S. Securities and Exchange Commission (the “Commission”) by letter dated June 17, 2024 (the “Comment
Letter”) regarding the above-referenced Registration Statement on Form S-1, originally confidentially submitted to
the Commission on April 10, 2024, as amended on May 15, 2024, and subsequently filed with the Commission on June 7, 2024.
Concurrently with the submission of this response letter, the Company is filing Amendment No. 1 to Registration Statement on Form S-1
(the “Registration Statement”) with the Commission. In addition to addressing the comments raised by the Staff
in the Comment Letter, the Company has included other revisions and updates to its disclosure in the Registration Statement.
For the convenience of the Staff, the numbering
of the paragraphs below corresponds to the numbering of the respective comment in the Comment Letter, the text of which we have incorporated
into this response letter for convenience in italicized type and which is followed by the Company’s response. In the responses
below, page number references are to the Registration Statement.
Registration Statement on Form S-1, Filed on June 7,
2024
Business
Manufacturing, page 132
1. Please disclose the names of your principal
suppliers. Refer to Regulation S-K Item 101(h)(4)(v).
Response:
In response to the Staff’s comment, the Company has revised the disclosure on page 131 of the Registration Statement
to disclose the Company’s principal suppliers of raw materials in accordance with Regulation S-K Item 101(h)(4)(v).
Cooley LLP 3 Embarcadero Center 20th Floor San
Francisco, CA 94111-4004
t: +1 415 693 2000 f: +1 415 693 2222 cooley.com
U.S. Securities and Exchange Commission
June 18, 2024
Page Two
Management
Composition of Our Board of Directors,
page 153
2. We note your revised disclosure that your
board of directors currently includes three vacancies, one of which you expect to fill prior
to the closing of this offering by mutual agreement of your board of directors pursuant to
the terms of a voting agreement. Given that your voting agreement provides certain of your
stockholders with the right to designate directors for election to your board of directors,
please revise your disclosure to clarify whether the vacancy you expect to fill is the vacancy
described in clause (vii) in the last paragraph on page 153.
Response:
In response to the Staff’s comment, the Company has revised the disclosure on page 152 of the Registration Statement.
The Company respectfully advises the Staff that it is actively working to identify and appoint a seventh director that meets the qualifications
of the Commission and the listing rules of the Nasdaq Stock Market and that it intends for its board of directors to appoint this additional
director as a Class III director prior to the launch of the offering. This director will be appointed pursuant to the Company's Voting Agreement (as defined in the Registration Statement) to fill the vacancy
described in clause (vii) in the last paragraph on page 152. The Company expects to lower the number of seats on its board of directors
to seven, effective at the closing of the offering.
Certain
Relationships and Related Person Transactions, page 176
3. We note that, in your discussion of your
related person transactions with the BBA Funds, you removed certain disclosures regarding
your former director's, Julian C. Baker's, relationship with the BBA Funds. Similarly, we
note that you removed disclosures regarding your transactions with venBio Global Strategic
Fund IV, L.P., an entity affiliated with your former director, Richard Gaster. To the extent
that these transactions occurred while Julian C. Baker and Richard Gaster, as applicable,
served as your directors and such persons had a direct or indirect material interest in the
respective transactions, please revise this section to add back the disclosures of these
relationships or otherwise advise.
Response:
In response to the Staff’s comment, the Company has revised the disclosures on pages 177 to 179 of the Registration
Statement.
* * *
Please contact me at (415) 693 2177 with any questions or further
comments regarding our responses to the Staff’s comments.
Sincerely,
/s/ Dave Peinsipp
Dave Peinsipp
cc:
Martin Babler, Alumis Inc.
Roy Hardiman, Alumis Inc.
Sara Klein, Alumis Inc.
Kristin
VanderPas, Cooley LLP
Cooley LLP 3 Embarcadero Center
20th Floor San Francisco, CA 94111-4004
t: +1 415 693 2000 f: +1 415 693 2222 cooley.com